Maland Medical (688273.SH) Reports 2025 Net Profit of RMB 102 Million, Up 0.47% Year-over-Year

Medlander (688273.SH) Releases 2025 Annual Earnings快报, Reporting Total Operating Revenue of 432 Million Yuan, a Year-on-Year Increase of 1.66%; Net Profit Attributable to Parent Company Owners of 102 Million Yuan, a Year-on-Year Increase of 0.47%.

During the reporting period, the company continued to strengthen brand building and channel optimization, laying a solid foundation for business development. The reproductive rehabilitation products maintained a stable advantage in niche markets and achieved steady growth. Meanwhile, to consolidate its technological edge and effectively respond to market changes, the company continuously increased investment in R&D and marketing. As a result, the net profit attributable to the parent company's shareholders remained basically flat compared with the same period last year.